Blog
RSS FeedPosted by Michael Wonder on 24 Jun 2020
ICER provides first update to pricing models for remdesivir as a treatment for COVID-19
24 June 2020 - Updated cost-recovery benchmark price now framed as a range with maximum of $1,600/10 day regimen when incorporating ...
Posted by Michael Wonder on 23 Jun 2020
The case for using novel value elements when assessing COVID-19 vaccines and therapeutics
23 June 2020 - In the span of mere weeks, the novel coronavirus (COVID-19) has upended modern life. Schools and businesses ...
Posted by Michael Wonder on 20 Jun 2020
ICER to assess whether the most significant prescription drug price increases are supported by new clinical evidence
19 June 2020 - Public input on drugs of concern will be accepted through 17 July 2020. ...
Posted by Michael Wonder on 16 Jun 2020
VA and ICER at three years: critics' concerns answered
15 June 2020 - As part of its national formulary management process, the Department of Veterans Affairs (VA) Pharmacy Benefits ...
Posted by Michael Wonder on 15 Jun 2020
COVID-19 and remdesivir: rethinking how we measure a drug’s ‘value’
15 June 2020 - As pharmaceutical and biotech companies scramble to identify treatments for COVID-19, a new disease that initially ...
Posted by Michael Wonder on 12 Jun 2020
ICER to assess treatments for high cholesterol
12 June 2020 - Report will be subject of a Midwest CEPAC meeting in February 2021; ppen Input now being ...
Posted by Michael Wonder on 26 May 2020
ICER releases draft evidence report on ulcerative colitis therapies
26 May 2020 - Public comment period now open until 29 July 2020; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 18 May 2020
International reference pricing gets thumbs down from ISPOR panel
18 May 2020 - International reference pricing, by which drug prices would be pegged to international standards, is under consideration ...
Posted by Michael Wonder on 14 May 2020
ICER’s cost model is not only wrong it’s also dangerous
11 May 2020 - There they go again. ...
Posted by Michael Wonder on 07 May 2020
How are incremental cost effectiveness, contextual considerations, and other benefits viewed in health technology assessment recommendations in the United States?
7 May 2020 - This study reviews ICER assessments to explore the relationship between incremental cost-effectiveness, other benefits, and contextual factors ...
Posted by Michael Wonder on 01 May 2020
The global imperative to make cancer medications affordable
1 May 2020 - The value of any medication is determined by the magnitude of the clinical benefit (improved survival and ...
Posted by Michael Wonder on 30 Apr 2020
Using QALYs versus DALYs to measure cost effectiveness: how much does it matter?
30 April 2020 - Quality-adjusted life-years and disability-adjusted life-years are commonly used in cost effectiveness analysis to measure health benefits. Gent ...
Posted by Michael Wonder on 27 Apr 2020
ICER releases evidence report on treatments for cystic fibrosis
27 April 2020 - Evidence on Trikafta provides high confidence of a substantial net health benefit for patients; additional benefits accrue ...
Posted by Michael Wonder on 16 Apr 2020
ICER Appoints Yvette Venable as Vice President of Patient Engagement
16 April 2020 - The Institute for Clinical and Economic Review has announced the appointment of Yvette Venable as the organisation’s ...
Posted by Michael Wonder on 19 Mar 2020
Getting value right: the case for indirect benefits
19 March 2020 - According to the most recent estimates from the Centers for Medicare and Medicaid Services Office of the ...